Clinical trial · Observational
A Retrospective Study on Extranodal DLBCL
The Retrospective Clinical Study of Extranodal Diffuse Large B-Cell Lymphoma
NCT06549361CI-TRIAL-00079705completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to prospectively collect clinical information of patients with extranodal DLBCL, assess the effectiveness of treatment for extranodal DLBCL in the real world, and explore the optimal treatment strategies in real-world populations.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
| Extranodal Lymphoma | Extranodal Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No interventions need to be specified for this study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Overall Survival (OS)
- timeFrame
- Time Frame: Baseline up to data cut-off (up to approximately 1 year)
- description
- Overall Survival (OS) will be defined from the start date of therapy to the date of death from any cause.
- measure
- Progression Free Survival (PFS)
- timeFrame
- Time Frame: Baseline up to data cut-off (up to approximately 1 year)
- description
- Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.
Secondary outcomes (1)
- measure
- Clinical characteristics form
- timeFrame
- Baseline up to data cut-off (up to approximately 1 year)
- description
- Clinical characteristics from data filled into registry forms by physicians and data managers, including but not limited to values of lactate dehydrogenase, clinical stage, performance status, age ≥ 60 years and number and location of extranodal localizations.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. ≥ 18 years (including 18 years). * 2\. Pathologically diagnosed with diffuse large B-cell lymphoma according to the 2016 WHO classification, including non-specific types and various special subtypes. * 3\. Newly diagnosed DLBCL with involvement of extranodal organs. * 4\. Patients who have received clinical treatment for lymphoma. * 5.Patients with measurable lesions, including at least one effective efficacy assessment. Exclusion Criteria: * 1\. Patients receiving supportive care only. * 2\. Patients who cannot obtain effective efficacy assessment data.
References
Publications (0)
Data not yet available
No reference posted for this study.